# Lantheus

Type: Company (LNTH)

Source: GetYourBrief — https://getyourbrief.com/entity/lantheus
Canonical HTML page: https://getyourbrief.com/entity/lantheus

## Recent coverage (4 stories, network-wide)

### Q4 2025 Biotech Earnings: CRISPR and Radiopharma Lead Growth
2026-02-26 22:32:41 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 12

The Q4 2025 earnings reports from leading biotech and specialty pharma firms reveal a sector-wide transition toward commercial-stage CRISPR therapies and high-growth radiopharmaceuticals. Key players like Intellia and Lantheus are setting the pace for 2026, while specialty firms focus on operational efficiency and non-opioid alternatives.
Full story: https://getbiobrief.com/story/q4-2025-biotech-earnings-analysis

### Earnings Preview: Frontdoor, Natera, Lantheus, and EVERTEC Set to Report
2026-02-25 05:15:03 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 4

A diverse group of mid-cap leaders across home services, healthcare, and fintech are preparing to release their quarterly results. Investors are focused on subscriber retention at Frontdoor and the continued clinical adoption of diagnostics at Natera and Lantheus.
Full story: https://getfinancebrief.com/story/earnings-preview-ftdr-ntra-lnth-evtc-2026

### Natera and Lantheus Earnings: Precision Diagnostics and Radiopharma in Focus
2026-02-25 05:15:00 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 4

As the Q4 2025 earnings cycle concludes, investors are prioritizing results from Natera and Lantheus to gauge the health of the liquid biopsy and radiopharmaceutical markets. These reports will provide critical data on the adoption of minimal residual disease (MRD) testing and the competitive dynamics of prostate cancer imaging.
Full story: https://getbiobrief.com/story/natera-lantheus-earnings-preview-biotech-diagnostics

### Precision Diagnostics and Radiopharma Lead Healthcare Q4 Earnings Outlook
2026-02-25 05:14:27 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 4

Investors are closely monitoring upcoming earnings from Natera and Lantheus as bellwethers for the precision medicine and radiopharmaceutical sectors. These reports will highlight the scaling of molecular residual disease testing and the competitive dynamics of advanced prostate cancer imaging.
Full story: https://gethealthbrief.com/story/natera-lantheus-earnings-preview-precision-medicine-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.